Key Drivers
- Positive cash flow
- High leverage
- Weak liquidity
AIAI Summary
Fortrea is no longer a pure growth play but a cash-generative restructuring story whose upside depends on sustained margin recovery and deleveraging rather than top-line expansion. Monitor two concrete triggers — consistent positive FCF used to pay down debt and sequential adjusted‑EBITDA margin expansion driven by conversion of backlog into higher‑margin early‑clinical work — because failure on either will keep the stock structurally discounted.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Positive cash flow
- •High leverage
- •Weak liquidity
FTRE generates positive operating and free cash flow but suffers large accounting losses, high leverage, weak liquidity, and strained coverage despite a tangible-book cushion.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Defined support
- •High volatility
Price fell ~13% over the last month to a confirmed low at $8.93, signaling a short-term downtrend with resistance near $10.5–$11.0 and elevated volatility (~19% peak-to-trough swing).
~19% swing from $11.01 peak to $8.93 low indicating elevated short-term volatility
Sentiment & News
Key News Insights:
- •Cost savings achieved
- •EPS miss
- •Leadership hires
Fortrea met revenue and cost‑savings targets and added clinical leadership but missed Q4 EPS, drawing cautious analyst sentiment and mixed institutional flows.
Shares likely face near‑term pressure from the EPS miss and tepid analyst ratings, while execution and talent additions provide medium‑term support
Similar Companies in Healthcare
Other companies in the same sector with AI ratings